STOCK TITAN

Insmed (INSM) Stock News, Nov 2020-Feb 2021

INSM NASDAQ

Insmed Incorporated develops and commercializes biopharmaceutical therapies for serious diseases, with a commercial respiratory portfolio that includes ARIKAYCE® (amikacin liposome inhalation suspension) and BRINSUPRI® (brensocatib). Its pipeline spans pulmonary, inflammatory, immunology and rare-disease programs, including TPIP and INS1148, alongside early research in gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining and synthetic rescue.

Recurring company news covers product revenue trends, regulatory authorizations and label-development activity for ARIKAYCE and BRINSUPRI, clinical data in MAC lung disease, non-cystic fibrosis bronchiectasis and inflammatory conditions, and presentations at medical and investor conferences. Updates also include portfolio-prioritization decisions, financial results, employee equity inducement grants and other governance-related announcements.

Rhea-AI Summary

Insmed Incorporated (Nasdaq: INSM) will release its fourth-quarter and full-year 2020 financial results on February 25, 2021. Management will host a conference call at 8:30 a.m. ET to discuss these results and provide a business update. Interested participants can join by dialing the provided numbers or via a live webcast. The replay of the call will be available two hours post completion until March 27, 2021. Insmed focuses on therapies for serious rare diseases, with its first product approved for a chronic lung disease.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.57%
Tags
conferences earnings date
-
Rhea-AI Summary

On February 5, 2021, Insmed Incorporated (Nasdaq: INSM) announced the granting of inducement awards to 14 new employees, in compliance with NASDAQ Listing Rule 5635(c)(4). These awards included options for a total of 65,980 shares of common stock at an exercise price of $37.44 per share, aligning with the closing price on February 1, 2021. The options have a ten-year term and a four-year vesting schedule, promoting employee retention and aligning interests with shareholder value.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.12%
Tags
none
-
Rhea-AI Summary

Insmed, a biopharmaceutical company focused on rare and serious diseases, will present at the 39th Annual J.P. Morgan Healthcare Conference on January 12, 2021, at 7:30 a.m. ET. This event will be available for live streaming and archived for 30 days. Insmed's mission is to improve patient lives through innovative therapies, including its first commercial product for a lung disease and a pipeline targeting unmet medical needs in inflammatory diseases and rare pulmonary disorders. More information can be found on www.insmed.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.09%
Tags
conferences
Rhea-AI Summary

Insmed announced that the first patient was dosed in December 2020 for the frontline clinical trial program of ARIKAYCE® in treating nontuberculous mycobacterial (NTM) lung disease caused by Mycobacterium avium complex (MAC). This program includes ARISE, a study validating patient-reported outcome tools, and ENCORE, a pivotal trial assessing ARIKAYCE's efficacy and safety. ARIKAYCE, the first FDA-approved therapy for MAC lung disease, aims to secure full approval and support supplemental drug applications. The trials seek to establish ARIKAYCE as a new standard of care.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.39%
Tags
-
Rhea-AI Summary

Insmed Incorporated (Nasdaq: INSM) announced on December 4, 2020, the granting of inducement awards to seven new employees as part of NASDAQ Listing Rule 5635(c)(4). Each employee received options to purchase a total of 13,560 shares at an exercise price of $39.14, reflecting the closing price on December 1, 2020. The options have a ten-year term and a four-year vesting schedule, with 25% vesting after one year and 12.5% every six months thereafter, contingent on continued employment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.59%
Tags
none
-
Rhea-AI Summary

Insmed announced the dosing of the first patient in the Phase 3 ASPEN study evaluating brensocatib for bronchiectasis treatment. This Phase 3 trial is centered on exploring the efficacy and safety of brensocatib, which has shown promising results in the Phase 2 WILLOW study. Approximately 1,620 patients across 40 countries will participate, with a primary focus on pulmonary exacerbation rates over 52 weeks. Brensocatib has received Breakthrough Therapy and PRIME designations, indicating its potential importance in addressing this serious condition.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.56%
Tags
Rhea-AI Summary

Insmed Incorporated (Nasdaq: INSM) announced its participation in the virtual Evercore ISI 3rd Annual HealthCONx Conference, scheduled for December 1, 2020, at 8:00 a.m. ET. This presentation aims to showcase the company's advancements in treating serious and rare diseases. The event will include a live webcast accessible through their investor relations page, with an archived version available for 30 days post-event. Insmed's mission focuses on transforming the lives of patients with chronic pulmonary diseases and other unmet medical needs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.45%
Tags
conferences
-
Rhea-AI Summary

Insmed announced that the European Medicines Agency (EMA) granted Priority Medicines (PRIME) designation to brensocatib for treating non-cystic fibrosis bronchiectasis (NCFBE). This designation aims to support drugs that address unmet medical needs. Brensocatib, an oral DPP1 inhibitor, is designed to reduce inflammation in NCFBE patients. Following positive Phase 2 trial results, Insmed plans to initiate the Phase 3 ASPEN trial by year-end 2020. Brensocatib also holds Breakthrough Therapy Designation from the FDA, enhancing its development prospects.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.82%
Tags
none
-
Rhea-AI Summary

Insmed announced on November 6, 2020, that it granted inducement awards to 10 new employees as per NASDAQ Listing Rule 5635(c)(4). The awards included options to purchase a total of 50,660 shares of common stock at an exercise price of $31.45 per share, the closing price on November 2, 2020. These options have a ten-year term and a four-year vesting schedule, with partial vesting occurring annually and semi-annually.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.96%
Tags
none
Rhea-AI Summary

Insmed, a global biopharmaceutical company, announced its participation in two upcoming virtual investor conferences. Management will present at the 29th Annual Credit Suisse Virtual Healthcare Conference on November 10, 2020, at 3:30 p.m. ET, and at the Stifel 2020 Virtual Healthcare Conference on November 17, 2020, at 10:00 a.m. ET. Both events will be webcast live, with recordings available for 30 days afterward. Insmed focuses on therapies for serious and rare diseases, including a first-in-disease therapy for chronic lung disease.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.52%
Tags
conferences

FAQ

What is the current stock price of Insmed (INSM)?

Insmed (INSM) last closed at $141.33.

What is the market cap of Insmed (INSM)?

The market cap of Insmed (INSM) is approximately $31.0B.